TokenPost·
Elutia Targets Q4 FDA Filing for Antibiotic-Coated NXT-41x Matrix
CEO Dr. Randy Mills projected a clearance decision in Q2 2027, within Elutia's broader first-half target. The reported antibacterial results came from a rabbit study.
More news
- DecryptThis Bitcoin Developer’s Idea Would Make Quantum Attacks a Losing Bet
- TokenPostInTest Corporation Projects Q4 2026 Revenue of $34 Million to $36 Million
- crypto.newsMichael Saylor hints at another Strategy Bitcoin buy as BTC trades near $76K
- TokenPostThailand SEC Files Criminal Complaint Against Bitget Operator, Plans Dec. 5 Block
- Bitcoin.com NewsBlue Wave, Red Week — Week in Review
- TokenPostOpenAI CFO Sarah Friar Says Valuation Is Nearly 50% Above March Round